The tesamorelin vs cjc-1295 ipamorelin decision is one of the most common conversations we have, and the answer is not always obvious from a Google search
Additional caution or monitoring may be appropriate in research settings involving: Pregnancy- or lactation-related research models, where limited safety data is available Active cancer-, tumor-, or abnormal proliferative research models, where NAD-related and metabolic-signaling pathways may influence cellular-signaling mechanisms Cardiovascular- or uncontrolled-hypertension research models, where metabolic-pathway modulation may influence cardiovascular-related biomarkers in some experimental settings Thyroid-related or endocrine research models, where metabolic-pathway investigations may influence endocrine-related observations Diabetes- or glucose-regulation research models, where insulin- and glucose-related pathways may warrant closer monitoring in experimental settings Moderate to severe hepatic- or renal-impairment research models, where compound metabolism or clearance mechanisms may be altered Autoimmune- or inflammatory-response research models, where immune-metabolic signaling pathways may influence inflammatory-related biomarkers or cytokine observations Research conditions, dosage ranges, administration frequency, protocol duration, and concurrent compounds may influence tolerability observations across experimental settings
Because knowing what to expect, and what to do when the unexpected happens, is the difference between abandoning a promising protocol and optimizing it for your goals
In research settings, NNMT inhibition is commonly used to explore how altering that branch point can shift the balance of methyl donor consumption, influence measurable pathway intermediates, and change downstream signatures that relate to energy handling, lipid pathways, and mitochondrial capacity depending on model and assay conditions
